Eosinophils: Novel perspectives in health and disease

Thursday, November 07, 2013 — Concurrent Symposia Session III
2:00 p.m. – 4:00 p.m.	FAES Academic Center lower-level Classrooms 6 and 7

Co-chairs

Helene Rosenberg, NIAID
Amy Klion, NIAID

Program

Eosinophils have been traditionally perceived as terminally differentiated cytotoxic effector cells. Studies carried out over the past few years, many of them here at NIH, have profoundly altered this simplistic view of eosinophils and their function. Recent basic, translational and clinical findings have generated a more sophisticated view of how eosinophils contribute to the pathogenesis of different diseases, including asthma and primary and secondary hypereosinophilic syndromes, and have also provided us with a more complete appreciation of the activities of these cells during parasitic infection.

Functionally Competent eosinophils differentiated ex vivo from unselected mouse bone marrow progenitors
Kimberly Dyer, NIAID

Role of macrophage CD163 in regulating airway eosinophilia in allergic asthma
Elizabeth Mushaben, NHLBI

Degranulating mouse eosinophils protect against lethal respiratory virus infection
Caroline Percopo, NIAID

Novel therapeutic targets for eosinophilic disorders; FARE Award Winner
Fanny Legrand, NIAID

Hematopoietic prostaglandin D synthase defines a pro-eosinophilic subset of highly differentiated Th2 cells
Alyssa Mitson-Salazar, NIAID

Glucocorticoid responsiveness in hypereosinophilic syndromes
Paneez Khoury, NIAID